These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 26068628)

  • 81. Hypothyroidism during treatment with tyrosine kinase inhibitors.
    Zygulska AL; Krzemieniecki K; Sowa-Staszczak A
    Endokrynol Pol; 2012; 63(4):302-6. PubMed ID: 22933166
    [TBL] [Abstract][Full Text] [Related]  

  • 82. International perspectives on treating advanced renal cell carcinoma.
    Tanimoto R
    Can J Urol; 2015 Jun; 22(3):7805. PubMed ID: 26068629
    [No Abstract]   [Full Text] [Related]  

  • 83. Acute aortic dissection in a patient with metastatic renal cell carcinoma treated with axitinib.
    Niwa N; Nishiyama T; Ozu C; Yagi Y; Saito S
    Acta Oncol; 2015 Apr; 54(4):561-2. PubMed ID: 25291078
    [No Abstract]   [Full Text] [Related]  

  • 84. Kidney cancer: TKIs associated with stroke risk.
    Fenner A
    Nat Rev Urol; 2015 Nov; 12(11):597. PubMed ID: 26502989
    [No Abstract]   [Full Text] [Related]  

  • 85. Kidney cancer: Axitinib destined for second place?
    Payton S
    Nat Rev Urol; 2013 Dec; 10(12):678. PubMed ID: 24217676
    [No Abstract]   [Full Text] [Related]  

  • 86. Hypertension among patients with renal cell carcinoma receiving axitinib or sorafenib: analysis from the randomized phase III AXIS trial.
    Rini BI; Quinn DI; Baum M; Wood LS; Tarazi J; Rosbrook B; Arruda LS; Cisar L; Roberts WG; Kim S; Motzer RJ
    Target Oncol; 2015 Mar; 10(1):45-53. PubMed ID: 24595903
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Osteonecrosis of the Jaw in Patients With Metastatic Renal Cell Cancer Treated With Bisphosphonates and Targeted Agents: Results of an Italian Multicenter Study and Review of the Literature.
    Fusco V; Porta C; Saia G; Paglino C; Bettini G; Scoletta M; Bonacina R; Vescovi P; Merigo E; Lo Re G; Guglielmini P; Di Fede O; Campisi G; Bedogni A
    Clin Genitourin Cancer; 2015 Aug; 13(4):287-294. PubMed ID: 25586958
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Five-year survival in patients with cytokine-refractory metastatic renal cell carcinoma treated with axitinib.
    Rini BI; de La Motte Rouge T; Harzstark AL; Michaelson MD; Liu G; Grünwald V; Ingrosso A; Tortorici MA; Bycott P; Kim S; Bloom J; Motzer RJ
    Clin Genitourin Cancer; 2013 Jun; 11(2):107-14. PubMed ID: 23391371
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Real-world chart review study of adverse events management in patients taking tyrosine kinase inhibitors to treat metastatic renal cell carcinoma.
    Srinivas S; Stein D; Teltsch DY; Tao S; Cisar L; Ramaswamy K
    J Oncol Pharm Pract; 2018 Dec; 24(8):574-583. PubMed ID: 28732453
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Kidney cancer: SWITCHing inconsequential.
    Thoma C
    Nat Rev Urol; 2015 Jun; 12(6):305. PubMed ID: 25986758
    [No Abstract]   [Full Text] [Related]  

  • 91. The influence of genetic variants of sorafenib on clinical outcomes and toxic effects in patients with advanced renal cell carcinoma.
    Qin C; Cao Q; Li P; Wang S; Wang J; Wang M; Chu H; Zhou L; Li X; Ye D; Zhang H; Huang Y; Dong B; Sun X; Zou Q; Cai H; Sun L; Zhu J; Liu F; Ji J; Cui L; Wang X; Zhou H; Zhao H; Wu B; Chen J; Jiang M; Zhang Z; Shao P; Ju X; Yin C
    Sci Rep; 2016 Feb; 6():20089. PubMed ID: 26830973
    [TBL] [Abstract][Full Text] [Related]  

  • 92. [Side effects of sorafenib and countermeasures].
    Nakayama M; Arai Y; Nishimura K
    Hinyokika Kiyo; 2012 Nov; 58(11):635-7. PubMed ID: 23254792
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Long-Term Safety With Axitinib in Previously Treated Patients With Metastatic Renal Cell Carcinoma.
    Rini BI; Escudier B; Hariharan S; Roberts WG; Tarazi J; Rosbrook B; Askerova Z; DeAnnuntis LL; Motzer RJ
    Clin Genitourin Cancer; 2015 Dec; 13(6):540-7.e1-7. PubMed ID: 26320662
    [TBL] [Abstract][Full Text] [Related]  

  • 94. MUC13 overexpression in renal cell carcinoma plays a central role in tumor progression and drug resistance.
    Sheng Y; Ng CP; Lourie R; Shah ET; He Y; Wong KY; Seim I; Oancea I; Morais C; Jeffery PL; Hooper J; Gobe GC; McGuckin MA
    Int J Cancer; 2017 May; 140(10):2351-2363. PubMed ID: 28205224
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Efficacy and safety of axitinib in elderly patients with metastatic renal cell carcinoma.
    Miyake H; Harada K; Ozono S; Fujisawa M
    Med Oncol; 2016 Aug; 33(8):95. PubMed ID: 27444960
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Adjuvant therapy for renal-cell carcinoma: settled for now.
    Duensing S; Hohenfellner M
    Lancet; 2016 May; 387(10032):1973-4. PubMed ID: 26969091
    [No Abstract]   [Full Text] [Related]  

  • 97. Metastatic involvement of the maxillary antrum from an uncommon source.
    Elledge R; Elledge RO; Raskauskiene D
    Dent Update; 2014 Apr; 41(3):230-2, 235. PubMed ID: 24839711
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Individualized Dosing of Axitinib Based on First-Dose Area Under the Concentration-Time Curve for Metastatic Renal-Cell Carcinoma.
    Miura Y; Imamura CK; Uchino K; Kishida T; Matsubara N; Shinojima T; Kondo K; Hongo F; Yoshimura K; Tanigawara Y; Takano T
    Clin Genitourin Cancer; 2019 Feb; 17(1):e1-e11. PubMed ID: 30529389
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Sequential molecularly targeted drug therapy including axitinib for a patient with end-stage renal failure and metastatic renal cell carcinoma.
    Nishida H; Fukuhara H; Yamagishi A; Sakurai T; Shibasaki T; Kawazoe H; Kato T; Tomita Y
    Hemodial Int; 2016 Apr; 20(2):E1-4. PubMed ID: 26306562
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Skull Base Metastasis From Occult Renal Cell Carcinoma.
    Golinelli G; Toso A; Rosa MS; Valletti PA; Pia F
    J Craniofac Surg; 2018 May; 29(3):e331-e333. PubMed ID: 29485573
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.